Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease

Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific “high-risk” populations, including congenital heart disease, bronchopu...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Hagan, Shaun, Galway, Niamh, Shields, Michael D, Mallett, Peter, Groves, Helen E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503506/
https://www.ncbi.nlm.nih.gov/pubmed/37720805
http://dx.doi.org/10.2147/DHPS.S348727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503506/
https://www.ncbi.nlm.nih.gov/pubmed/37720805
http://dx.doi.org/10.2147/DHPS.S348727

Ejemplares similares